[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625298":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":41,"centralContacts":57,"locations":63,"responsibleParty":82,"collaborators":41,"id":84,"slug":41,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":41,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":41,"overallStatus":104,"whyStopped":41,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Apsen Farmaceutica S.A.","INDUSTRY",[8,14,18,22,26,31],{"label":9,"type":10,"description":11,"interventionNames":12},"APSTZD 1","EXPERIMENTAL","5 oral tablets, once a day, before bedtime, for 6 weeks.",[13],"Drug: APSTZD 1",{"label":15,"type":10,"description":11,"interventionNames":16},"APSTZD 2",[17],"Drug: APSTZD 2",{"label":19,"type":10,"description":11,"interventionNames":20},"APSTZD 3",[21],"Drug: APSTZD 3",{"label":23,"type":10,"description":11,"interventionNames":24},"APSTZD 4",[25],"Drug: APSTZD 4",{"label":27,"type":28,"description":11,"interventionNames":29},"Stilnox CR®","ACTIVE_COMPARATOR",[30],"Drug: Stilnox CR®",{"label":32,"type":33,"description":11,"interventionNames":34},"Placebo","PLACEBO_COMPARATOR",[35],"Drug: Placebo",[37,42,45,48,51,54],{"type":38,"name":9,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","APSTZD + placebo test 2 + placebo test 3 + placebo test 4 + comparator placebo 1",[9],null,{"type":38,"name":15,"description":43,"armGroupLabels":44,"otherNames":41},"APSTZD + placebo test 1 + placebo test 3 + placebo test 4 + comparator placebo 1",[15],{"type":38,"name":19,"description":46,"armGroupLabels":47,"otherNames":41},"APSTZD + placebo test 1 + placebo test 2 + placebo test 4 + comparator placebo 1",[19],{"type":38,"name":23,"description":49,"armGroupLabels":50,"otherNames":41},"APSTZD + placebo test 1 + placebo test 2 + placebo test 3 + comparator placebo 1",[23],{"type":38,"name":27,"description":52,"armGroupLabels":53,"otherNames":41},"Stilnox CR® + placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4",[27],{"type":38,"name":32,"description":55,"armGroupLabels":56,"otherNames":41},"placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4 + comparator 1",[32],[58],{"name":59,"role":60,"phone":61,"phoneExt":41,"email":62},"Fernanda Martinez Scalzaretto","CONTACT","+551156448200","fernanda.martinez@apsen.com.br",[64],{"facility":65,"status":41,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"UNIFAG - Casa Nossa Senhora da PAZ -ASF","Bragança Paulista","São Paulo","12916-900","Brazil","BR",{"type":72,"coordinates":73},"Point",[74,75],-46.54418,-22.9527,{"lat":75,"lon":74},[78],{"name":79,"role":60,"phone":80,"phoneExt":41,"email":81},"Rafaella Santos Dantas Beltrame","+55(35)98833-9715","rafaellasantosdantas@gmail.com",{"type":83,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100625298",false,"NCT07420816","Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","TINA","Inclusion Criteria:\n\n* Participants aged between 18 and 64 years;\n* Participants diagnosed with insomnia disorder according to the criteria defined by the DSM-V (1) and who report sleep maintenance disorder;\n* Participants who agree not to use alcoholic beverages during the entire treatment period (6 weeks).\n\nExclusion Criteria:\n\n* Participants with known hypersensitivity to the active ingredients used during the trial or who have exhibited complex sleep behavior after using them;\n* Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;\n* Women who are pregnant or breastfeeding, as well as women who have a positive result on a pregnancy test (β-hCG) during the screening period of the trial;\n* Participants diagnosed with severe liver failure;","ALL","18 Years","64 Years",{"count":95,"type":96},222,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.",[102,103],"Insomnia","Insomnia Chronic","NOT_YET_RECRUITING","2026-02-12",{"date":107,"type":108},"2026-02-19","ACTUAL",{"date":110,"type":96},"2026-03-26",{"date":112,"type":96},"2027-09-23",{"name":5,"class":6},1]